Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

• ClinicalTrials.gov Identifier: NCT03050554
• Recruitment Status: Active, not recruiting
• First Posted: February 13, 2017
• Last Update Posted: March 20, 2019
• Sponsor: Andrew Sharabi
• Collaborator: Pfizer
• Information provided by (Responsible Party): Andrew Sharabi, University of California, San Diego

Study Description

Brief Summary:

The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).

Avelumab is considered experimental because it is not approved by the United States (U.S.) Food and Drug Administration (FDA) for the treatment of cancer. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies are made to recognize, target and bind to specific proteins on the cells that make up your tissues. Avelumab is designed to block the interaction between PD-1, a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer.

Stereotactic Body Radiation Therapy (SBRT) is a type of radiation that uses precise targeting to deliver a high dose of radiation to the tumor over a short period of time. A positioning cushion such as Vac-lok will be used during radiation treatment that is custom made. This custom mold forms to the contours of the subjects body to allow for proper positioning comfort and stability.

Condition or disease	Intervention/treatment	Phase
Early Stage Non-Small Cell Lung Cancer	Drug: Avelumab; Radiation: SBRT	Phase 1; Phase 2

Detailed Description:

This is a single arm open label Phase I/II study that will consist of two parts. In Phase I, investigators will assess the safety and tolerability of SBRT combined with Avelumab. In Phase II, investigators will determine whether SBRT combined with Avelumab improves relapse free survival. Subjects with Stage I NSCLC who are not undergoing surgical resection will be candidates for enrollment. Subjects will receive definitive stereotactic body radiation (SBRT) in 4-5 fractions combined with concurrent and adjuvant Avelumab at 10mg/kg for a total of 6 cycles. Subjects will be evaluated for safety as measured by the occurrence of adverse events, serious adverse events, and laboratory abnormalities. Three blood draws will be obtained to analyze anti-tumor immune responses and immune correlates.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 2 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
• Actual Study Start Date: October 26, 2017
• Estimated Primary Completion Date: October 2020
• Estimated Study Completion Date: October 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: SBRT+Avelumab; SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.) Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles	Drug: Avelumab; Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles; Radiation: SBRT; SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Outcome Measures

Primary Outcome Measures :

1. Safety and tolerability of definitive SBRT combined with concurrent and adjuvant Avelumab in patients with early stage NSCLC (Measured Via Adverse Events). [ Time Frame: 6 months ]
   Measured Via Adverse Events
2. Relapse free survival (RFS) [ Time Frame: 3 years ]
   Relapse-Free Survival (RFS) is defined as the time from starting treatment to the time of first documented tumor progression or death due to any cause, whichever occurs first. Death is considered as an event here.

Secondary Outcome Measures :

1. Loco-regional control (LRC) [ Time Frame: 3 years ]
   Locoregional Control (LRC) is defined as the time from starting treatment until local and/or regional relapse is documented
2. Overall survival in patients after completion of SBRT in combination with Avelumab [ Time Frame: 3 years ]
   Overall survival in patients is defined as the time from after completion of SBRT in combination with Avelumab

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Tumor(s) to be treated is(are) ≤ 5.0 cm or ≤250 cm3
• Stage I NSCLC and is deemed medically inoperable or refuses surgical resection.
• Life expectancy ≥ 9 months.
• Acceptable organ and marrow function

Exclusion Criteria:

• Prior organ transplantation, including allogeneic stem cell transplantation

• Significant acute or chronic infections including:

  • Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Known history of HBV or HCV

• Active autoimmune disease

  • Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
  • Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable

• Current use of immunosuppressive medication, EXCEPT for the following:

  • intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection)
  • Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent
  • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
• Cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
• Known severe hypersensitivity reactions to monoclonal antibodies any history of anaphylaxis, or uncontrolled asthma
• Pregnancy or lactation
• Known alcohol or drug abuse
• Prior radiotherapy to the treatment site(s).

Contacts and Locations

Locations

United States, California

UC San Diego Moores Cancer Center

La Jolla, California, United States, 92093

United States, South Dakota

Sanford Health

Sioux Falls, South Dakota, United States, 57104

Sponsors and Collaborators

Andrew Sharabi

Pfizer

Investigators

• Principal Investigator: Andrew Sharabi, M.D., Ph.D.; University of California, San Diego

More Information

• Responsible Party: Andrew Sharabi, Assistant Clinical Professor, University of California, San Diego
• ClinicalTrials.gov Identifier: NCT03050554
• Other Study ID Numbers: 161591
• First Posted: February 13, 2017
• Last Update Posted: March 20, 2019
• Last Verified: March 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Andrew Sharabi, University of California, San Diego:

cancer; Non-Small Cell Lung Cancer; SBRT; Avelumab; Stereotactic Body Radiation Therapy; radiation; NSCLC; PD-1; PD-L1; Immunotherapy; Lung

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms